PDSB.NASDAQPds Biotechnology CORP

10-Q: PDS Biotechnology Reports Third Quarter 2024 Financial Results and Provides Clinical Pipeline Update

Sentiment:

Quarterly Report

📋All filings for Pds Biotechnology CORP
🔒Login to Follow

PDS Biotechnology reported a net loss of $10.7 million for the third quarter of 2024, while continuing to advance its clinical programs.

Capital raiseThe company plans to continue to fund its operations and capital funding needs through existing cash and additional equity and/or debt financing.The company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization.The sale of additional equity would result in additional dilution to the company's stockholders.Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict its operations.
Worse than expectedThe company has concluded that substantial doubt exists about its ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.

Summary

  • PDS Biotechnology Corporation reported a net loss of $10.7 million for the three months ended September 30, 2024, compared to a net loss of $10.8 million for the same period in 2023.
  • The company's research and development expenses increased slightly to $6.8 million for the quarter, while general and administrative expenses decreased to $3.4 million.
  • For the nine months ended September 30, 2024, the net loss was $29.7 million, compared to $32.0 million for the same period in 2023.
  • The company's cash and cash equivalents totaled $49.8 million as of September 30, 2024.
  • PDS Biotech is a clinical-stage immunotherapy company focused on developing targeted immunotherapies for cancer and infectious diseases.
  • The company is advancing its Versamune and PDS01ADC platforms in oncology and Infectimune in infectious diseases.
  • The company has a loan agreement with Horizon Technology Finance Corporation with principal payments commencing October 1, 2024.
  • The company has raised $19.4 million through the sale of common stock during the nine months ended September 30, 2024.
  • The company has concluded that substantial doubt exists about its ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical trial updates and strategic collaborations, the company's financial losses, going concern uncertainty, and need for additional capital raise concerns. The sentiment is therefore cautiously negative.

Positives

  • The company has $49.8 million in cash and cash equivalents.
  • The company is actively advancing its clinical programs with multiple ongoing trials.
  • The company has a strategic collaboration with the NCI for several clinical trials.
  • The company has a global license agreement with Merck KGaA for PDS01ADC.
  • The company has shown promising clinical data for its Versamune HPV and PDS01ADC combinations.
  • The company has received Fast Track designation from the FDA for VersamuneHPV in combination with Keytruda.

Negatives

  • The company reported a net loss of $10.7 million for the third quarter of 2024.
  • The company has an accumulated deficit of $174.2 million.
  • The company has no commercial product revenue.
  • The company has concluded that substantial doubt exists about its ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.
  • The company is dependent on additional financing to fund its operations.

Risks

  • The company's ability to obtain regulatory approvals for its product candidates is uncertain.
  • The company's ability to raise additional capital is not guaranteed.
  • The company's clinical trials may not be successful.
  • The company faces competition from other biotechnology and pharmaceutical companies.
  • The company's intellectual property may not be adequately protected.
  • The company's loan agreement with Horizon Technology Finance Corporation has covenants that could restrict operations.
  • The company's ability to continue as a going concern is in doubt.

Future Outlook

The company plans to continue to fund its operations and capital funding needs through existing cash and additional equity and/or debt financing, and may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. However, there is no assurance that sufficient additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or its existing shareholders.

Management Comments

  • The company is focused on advancing its Versamune and PDS01ADC platforms in oncology and Infectimune in infectious diseases.
  • The company believes its investigational targeted immunotherapies have the potential to overcome limitations of current immunotherapy approaches.
  • The company is working closely with the NCI to determine the best pathway forward for the prioritized PDS01ADC studies.

Industry Context

The company operates in the competitive biotechnology industry, focusing on developing novel immunotherapies for cancer and infectious diseases. The company's approach of combining Versamune with PDS01ADC and immune checkpoint inhibitors is aligned with the industry trend of exploring combination therapies to enhance treatment efficacy. The company's focus on T cell activation and tumor microenvironment modulation is also consistent with current research directions in immuno-oncology.

Comparison to Industry Standards

  • The company's reported median overall survival of 30 months in the VERSATILE-002 trial for the combination of Versamune HPV and Keytruda compares favorably to published results of 7-18 months for ICIs alone in similar patient populations.
  • The company's reported objective response rate of 36% in the VERSATILE-002 trial is higher than the 19-25% typically seen with pembrolizumab alone.
  • The company's reported median overall survival of approximately 20 months in ICI resistant patients treated with the triple combination of Versamune HPV, PDS01ADC, and an investigational ICI is significantly higher than the historical median OS of 3-4 months seen with checkpoint inhibitors and the best reported median survival to date with systemic therapy of 8.2 months in ICI resistant head and neck cancer.
  • The company's reported 75% survival rate at 36 months in ICI nave patients treated with the triple combination is higher than the published median overall survival of 7-11 months in similar patients.
  • The company's reported disease control rate of 77% in the VERSATILE-002 trial is higher than the typical rates seen with ICIs alone.
  • The company's reported Grade 3 treatment-related adverse events of 9 patients (Grade 3, n=8 and Grade 4, n=1) in the VERSATILE-002 trial is comparable to or lower than the 13-17% Grade 3-5 TRAE reported with approved ICI monotherapy.

Stakeholder Impact

  • Shareholders may experience dilution from future equity raises.
  • Employees may be impacted by potential cost-cutting measures if the company faces financial difficulties.
  • Customers (potential patients) may benefit from the development of new immunotherapies.
  • Suppliers and creditors may face increased risk due to the company's going concern uncertainty.

Next Steps

  • The company plans to initiate a registrational study in first line treatment in HPV16-positive recurrent/metastatic HNSCC with the double combination of Versamune HPV + pembrolizumab.
  • The company will continue to work with the NCI to determine the best pathway forward for the prioritized PDS01ADC studies.
  • The company will continue to evaluate the use of PDS01ADC in combination with other Versamune based clinical candidates.
  • The company will continue to evaluate the next steps in the clinical development and funding for PDS0202.

Key Dates

DateDescription
March 5, 2020The company entered into a sublease for office space in Florham Park, NJ.
May 1, 2020The sublease for office space in Florham Park, NJ commenced.
June 2020The first patient was dosed in the NCI-led Phase 2 trial evaluating Versamune HPV with PDS01ADC and Bintrafusp alfa.
October 2020A Phase 2 Investigator Initiated Trial (IIT) was initiated with The University of Texas MD Anderson Cancer Center.
November 2020The VERSATILE-002 Phase 2 clinical trial commenced.
January 1, 2021The company was no longer an emerging growth company.
February 2021The NCI's Phase 2 clinical trial of Versamune HPV achieved its preliminary objective response target.
February 2022The company achieved the preliminary efficacy milestone in the ICI nave arm of the VERSATILE-002 trial and initiated an IIT at Mayo Clinic.
May 17, 2022The company amended the Inducement Plan to increase the total number of shares of Common Stock reserved for issuance.
June 2022The company presented preliminary efficacy and safety data from the VERSATILE-002 trial at the ASCO Annual Meeting and received Fast Track designation from the FDA.
August 2022The company filed a shelf registration statement and entered into an At Market Issuance Sales Agreement and a venture loan and security agreement.
September 2, 2022The 2022 Shelf Registration Statement was declared effective.
December 2022The company entered into an exclusive global license agreement with Merck KGaA for PDS01ADC and presented interim data from the NCI trial.
February 2023The company announced the completion of a Type B meeting with the FDA for the triple combination therapy.
April 2023The company received approximately $1.4 million from the net sale of tax benefits.
May 2023The company completed enrollment in the ICI nave arm of the VERSATILE-002 trial.
June 2023An abstract was presented at the 2023 American Society of Clinical Oncology.
July 14, 2023The stockholders approved the Third Restated Plan.
July 31, 2023The option to advance Loan E and Loan F expired.
September 2023Data on the company's investigational universal flu vaccine was presented at the ESWI conference.
October 2023Data was presented at the American Society for Radiation Oncology Annual Meeting, a key opinion leader roundtable, and the International Cytokine & Interferon Society Annual Meeting.
November 2023The company announced updated survival data from the NCI-led Phase 2 trial and presented preclinical data at the Society for Immunotherapy of Cancer 38th Annual Meeting.
January 22, 2024The company amended the Inducement Plan to increase the total number of shares of Common Stock reserved for issuance.
April 2024The company received approximately $0.9 million from the net sale of tax benefits.
May 2024The company presented updated interim data from the VERSATILE-002 Phase 2 clinical trial at a virtual key opinion leader event.
June 2024The company provided a data update from the VERSATILE-002 clinical trial.
August 2024The company entered into an Amended and Restated At Market Issuance Sales Agreement and provided an update to its clinical strategy.
September 2024The company announced updated data from the VERSATILE-002 Phase 2 clinical trial at the ESMO Congress 2024.
September 30, 2024The end of the reporting period for the quarterly report.
October 1, 2024Principal payments on the loan agreement begin.
November 7, 2024The number of shares of the company's common stock outstanding was 37,409,137.
November 14, 2024The date of the quarterly report.

Keywords

immunotherapy, oncology, infectious diseases, Versamune, PDS01ADC, Infectimune, clinical trials, cancer, T cells, FDA, biotechnology, pharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.